Peptides for Senior dog mobility in Dogs
The short answer
For senior dog mobility in dogs, the compounds under investigation are BPC-157, TB-500, IGF-1 LR3 — of which BPC-157 has the strongest evidence base, graded emerging. The combined effect of arthritis, muscle loss, and reduced activity that limits older dogs. No compound described here is FDA-approved for this use in dogs, and none should be started without veterinary involvement.
About the condition
Declining mobility in an older dog is rarely one problem. Arthritis makes movement uncomfortable, discomfort reduces activity, inactivity accelerates muscle loss, and weaker muscle destabilises the joints further. Neurological changes and reduced proprioception often overlay all of it. Because the causes are multiple, this is an area where a single compound rarely addresses the whole picture, and where the value of any protocol is best judged on functional outcomes — is the dog rising more easily, walking further, climbing stairs again — rather than on any measurement. One caution specific to this group: two of the compounds below, TB-500 and IGF-1 LR3, are contraindicated in dogs with malignancy, and older dogs are precisely the population most likely to be carrying an undiagnosed one. Screening comes before either of them, not after.
Compounds investigated for this condition
Ranked by strength of the published evidence.
The only peptide on this site with published canine pharmacokinetic data.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Full BPC-157 profile, dosing and safety →A thymosin beta-4 fragment studied for tissue repair, and well characterised in equine doping-control literature.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Full TB-500 profile, dosing and safety →An engineered IGF-1 analogue with a half-life measured in days rather than minutes.
IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone that mediates most of growth hormone's effects on muscle. The modification reduces how tightly it binds the carrier proteins that normally hold IGF-1 in circulation, leaving more of it free to reach the receptor. Protocols circulating online describe this as extending its active life to twenty or thirty hours, but no peer-reviewed pharmacokinetic study establishes that figure, and it sits awkwardly with the underlying pharmacology — binding to those carrier proteins is what normally protects IGF-1 from being cleared, so reducing that binding would be expected to shorten its time in circulation rather than lengthen it. What is not in doubt is that it signals more freely than native IGF-1, and that is the reason it demands the most caution of any compound here.
Full IGF-1 LR3 profile, dosing and safety →Critical safety notes
These apply to the compounds listed above and should be read before considering any of them.
⚠ TB-500: Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
⚠ IGF-1 LR3: Contraindicated with active cancer
IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory.
⚠ IGF-1 LR3: Hypoglycaemia risk
IGF-1 LR3 has insulin-like activity and can lower blood glucose. Tremors, disorientation, weakness, or collapse are emergencies. Blood glucose must be monitored, and diabetic dogs require direct veterinary management.
Common questions
What peptides are used for senior dog mobility in dogs?+
BPC-157, TB-500, IGF-1 LR3 are the compounds investigated for senior dog mobility in dogs. BPC-157 carries the strongest evidence of these, graded as emerging evidence. None are FDA-approved for this use in dogs.
Do peptides actually help senior dog mobility in dogs?+
The honest answer is that the canine evidence is limited. The combined effect of arthritis, muscle loss, and reduced activity that limits older dogs. The compounds investigated here have mechanistic support and, in some cases, published animal data — but controlled clinical trials in dogs with senior dog mobility have not been conducted. Any use is investigational and belongs in a conversation with your veterinarian rather than a decision made independently.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
- 12.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
- 13.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.